489,485 Shares in Vir Biotechnology, Inc. (NASDAQ:VIR) Acquired by Alta Partners Management Company L.P.

Alta Partners Management Company L.P. purchased a new position in Vir Biotechnology, Inc. (NASDAQ:VIR) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 489,485 shares of the company’s stock, valued at approximately $3,593,000. Vir Biotechnology accounts for about 5.7% of Alta Partners Management Company L.P.’s portfolio, making the stock its 2nd largest holding. Alta Partners Management Company L.P. owned approximately 0.36% of Vir Biotechnology as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Blue Trust Inc. grew its holdings in Vir Biotechnology by 143.5% during the 3rd quarter. Blue Trust Inc. now owns 3,989 shares of the company’s stock valued at $30,000 after buying an additional 2,351 shares during the last quarter. KBC Group NV grew its holdings in Vir Biotechnology by 136.5% during the 4th quarter. KBC Group NV now owns 8,970 shares of the company’s stock valued at $66,000 after buying an additional 5,177 shares during the last quarter. CIBC Asset Management Inc acquired a new stake in Vir Biotechnology during the 4th quarter valued at $74,000. Captrust Financial Advisors acquired a new stake in Vir Biotechnology during the 3rd quarter valued at $118,000. Finally, Quarry LP grew its holdings in Vir Biotechnology by 901.8% during the 3rd quarter. Quarry LP now owns 17,000 shares of the company’s stock valued at $127,000 after buying an additional 15,303 shares during the last quarter. Institutional investors and hedge funds own 65.32% of the company’s stock.

Vir Biotechnology Trading Up 3.5 %

Shares of VIR opened at $8.39 on Friday. The firm has a market capitalization of $1.16 billion, a P/E ratio of -2.14 and a beta of 0.64. The stock’s fifty day simple moving average is $9.46 and its 200 day simple moving average is $8.49. Vir Biotechnology, Inc. has a twelve month low of $6.56 and a twelve month high of $14.45.

Vir Biotechnology (NASDAQ:VIR) last issued its earnings results on Wednesday, February 26th. The company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.09. The business had revenue of $12.37 million for the quarter, compared to analyst estimates of $8.14 million. Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. Sell-side analysts predict that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current year.

Insider Buying and Selling

In other Vir Biotechnology news, Director Vicki L. Sato sold 10,960 shares of the firm’s stock in a transaction dated Wednesday, January 8th. The stock was sold at an average price of $12.52, for a total value of $137,219.20. Following the transaction, the director now directly owns 1,312,391 shares of the company’s stock, valued at $16,431,135.32. This trade represents a 0.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Verneuil Vanina De sold 7,373 shares of the firm’s stock in a transaction dated Wednesday, February 26th. The shares were sold at an average price of $9.14, for a total value of $67,389.22. Following the completion of the transaction, the executive vice president now directly owns 79,460 shares in the company, valued at $726,264.40. This trade represents a 8.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 30,935 shares of company stock valued at $327,082. 15.60% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. Leerink Partners raised their price objective on Vir Biotechnology from $18.00 to $20.00 and gave the stock an “outperform” rating in a report on Monday, January 13th. HC Wainwright restated a “buy” rating and set a $110.00 price objective on shares of Vir Biotechnology in a report on Friday. JPMorgan Chase & Co. raised their price objective on Vir Biotechnology from $10.00 to $14.00 and gave the stock a “neutral” rating in a report on Thursday, January 9th. Barclays raised their price objective on Vir Biotechnology from $26.00 to $31.00 and gave the stock an “overweight” rating in a report on Friday. Finally, Needham & Company LLC restated a “buy” rating and set a $19.00 price objective on shares of Vir Biotechnology in a report on Thursday. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $35.67.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).